MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/bjd/ljad459

Медицинская библиотека · The British journal of dermatology · 2024

Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma.

Ewen Tom, Husain Akhtar, Stefanos Niki, Barrett Paul, Jones Claire, Ness Tom, Long Anna, Horswell Stuart, Bosomworth Helen, Lowenstein Joe, Richardson Grant, Swan David, McConnell Ashleigh, Rose Aidan, Andrew Tom, Reynolds Nick, Malvehy Josep, Carrera Christina, Alos Llucia, Mailer Sonia, Helm Thomas, Ding Liang, Bogner Paul, Podlipnik Sebastian, Puig Susana, McArthur Grant A, Paragh Gyorgy, Labus Marie, Sloan Philip, Armstrong Jane L, Lovat Penny E

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Combined expression of the autophagy-regulatory protein AMBRA1 (activating molecule in Beclin1-regulated autophagy) and the terminal differentiation marker loricrin in the peritumoral epidermis of stage I melanomas can identify tumour subsets at low risk of -metastasis.

OBJECTIVES

To validate the combined expression of peritumoral AMBRA1 and loricrin (AMBLor) as a prognostic biomarker able to identify both stage I and II melanomas at low risk of tumour recurrence.

METHODS

Automated immunohistochemistry was used to analyse peritumoral AMBRA1 and loricrin expression in geographically distinct discovery (n = 540) and validation (n = 300) cohorts of nonulcerated American Joint Committee on Cancer (AJCC) stage I and II melanomas. AMBLor status was correlated with clinical outcomes in the discovery and validation cohorts separately and combined.

RESULTS

Analysis of AMBLor in the discovery cohort revealed a recurrence-free survival (RFS) rate of 95.5% in the AMBLor low-risk group vs. 81.7% in the AMBLor at-risk group (multivariate log-rank, P < 0.001) and a negative predictive value (NPV) of 96.0%. In the validation cohort, AMBLor analysis revealed a RFS rate of 97.6% in the AMBLor low-risk group vs. 78.3% in the at-risk group (multivariate log-rank, P < 0.001) and a NPV of 97.6%. In a multivariate model considering AMBLor, Breslow thickness, age and sex, analysis of the combined discovery and validation cohorts showed that the estimated effect of AMBLor was statistically significant, with a hazard ratio of 3.469 (95% confidence interval 1.403-8.580, P = 0.007) and an overall NPV of 96.5%.

CONCLUSIONS

These data provide further evidence validating AMBLor as a prognostic biomarker to identify nonulcerated AJCC stage I and II melanoma tumours at low risk of disease recurrence.

Для цитирования: Ewen Tom, Husain Akhtar, Stefanos Niki, Barrett Paul, Jones Claire, Ness Tom, Long Anna, Horswell Stuart, Bosomworth Helen, Lowenstein Joe, Richardson Grant, Swan David, McConnell Ashleigh, Rose Aidan, Andrew Tom, Reynolds Nick, Malvehy Josep, Carrera Christina, Alos Llucia, Mailer Sonia, Helm Thomas, Ding Liang, Bogner Paul, Podlipnik Sebastian, Puig Susana, McArthur Grant A, Paragh Gyorgy, Labus Marie, Sloan Philip, Armstrong Jane L, Lovat Penny E. Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma.. The British journal of dermatology. 2024. DOI: 10.1093/bjd/ljad459.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.